L. Cammelli

University of Vienna

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

A. E. Pontiroli

University of Milan

G. Pozza

Vita-Salute San Raffaele University

C. Socci

Vita-Salute San Raffaele University

Guido Ferrari

Duke University

C. Staudacher

San Raffaele University of Rome

A. Dubini

IRCCS Istituto Auxologico Italiano

V Di Carlo

London School of Hygiene & Tropical Medicine

Camillo Ricordi

University of Miami

Ruggero Mangili

Azienda Socio Sanitaria Territoriale Bergamo Est

Marco Stella

Ente Ospedaliero Ospedali Galliera

Cooperative Institutions

University of Milan

San Raffaele University of Rome

Istituti di Ricovero e Cura a Carattere Scientifico

Vita-Salute San Raffaele University

IRCCS Ospedale San Raffaele

Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele

University of Vienna

University of Miami

Medica (Italy)

University of Genoa

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Inhibition of Basal and Metoclopramide-Induced Prolactin Release by Cabergoline, an Extremely Long-Acting Dopaminergic Drug

The Journal of Clinical Endocrinology & Metabolism (1987)

A. E. Pontiroli L. Cammelli Paolo Baroldi G. Pozza

The aim of this study was to evaluate the effectiveness of the ergoline derivative cabergoline in inhibiting the serum PRL response to metoclopramide (MCP; 5 mg, iv) and the duration of this effect. Seven normal men received cabergoline (600 micrograms, orally) on day 0 and underwent a MCP test on days -1, 1, 4, 8, 15, and 28. Fasting serum PRL levels were significantly depressed from days 1-14; the nadir value occurred on day 4. MCP-induced PRL release was significantly inhibited up to day 28, with a nadir on day 4. Two months later, four of the men received placebo on day 0, and tests with MCP were performed on days -1, 8, and 28; basal serum PRL levels and PRL responses to MCP were superimposable on days -1, 8, and 28. These data indicate that cabergoline is an effective long-acting inhibitor of PRL release in normal men, suitable for use in the management of hyperprolactinemic patients.

Cabergoline

Metoclopramide

Basal (medicine)

10.1210/jcem-65-5-1057

Cite

Citations (22)

Effects of oral administration of maltitol on plasma glucose, plasma sorbitol, and serum insulin levels in man

Klinische Wochenschrift (1986)

Antonio Secchi A. E. Pontiroli L. Cammelli A. Bizzi Michela Cini

Maltitol

10.1007/bf01711933

Cite

Citations (21)

[Isolation of the islands of Langerhans of the rat pancreas and evaluation of islet function in vitro].

PubMed (1985)

C. Staudacher Camillo Ricordi Marco Stella C. Socci L. Cammelli

Isolation

Source

Cite

Citations (1)

Selective and extremely long inhibition of prolactin release in man by 1‐ethyl‐3‐(3′‐dimethylaminopropyl)‐3‐(6′‐allylergoline‐8′‐beta‐ carbonyl)‐urea‐diphosphate (FCE 21336).

British Journal of Clinical Pharmacology (1987)

A. E. Pontiroli Gc Viberti Ruggero Mangili L. Cammelli A. Dubini

The effects on anterior pituitary function of FCE 21336 (1‐ethyl‐3‐(3′‐ dimethylaminopropyl)‐3‐(6′‐allylergoline‐8′‐beta‐ca rbonyl)‐urea‐ diphosphate), a synthetic ergoline derivative with selective dopamine agonistic properties, were studied. Circulating PRL, GH, TSH, cortisol and LH levels were determined up to 96 h after single oral doses of 50, 100, 200 and 300 micrograms of the compound to eight healthy males, and up to 168 h after single oral doses of 400 and 600 micrograms to six healthy males, according to double‐blind, within subjects, experimental designs vs placebo. Vital signs, ECG, laboratory tests and the appearance of newly observed signs and symptoms were monitored. A dose‐ related decrease of serum PRL in comparison with both basal and post‐ placebo levels was observed after 200 micrograms and greater doses of the compound, with inhibition of spontaneous circadian rhythm. Maximal inhibition (PRL less than 2 ng ml‐1) was observed in one out of five subjects after 200, three out of seven subjects after 300, four out of six after 400 and five out of six subjects after 600 micrograms. The effect was of rapid onset and long duration; the maximum or nearly maximum decrease was observed within 3 h after dosing as well as up to 96 h (200 and 300 micrograms) and up to 168 h (400 and 600 micrograms). No modifications of GH, TSH, LH and cortisol as well as of vital signs, ECG and laboratory tests were apparent.(ABSTRACT TRUNCATED AT 250 WORDS)

Basal (medicine)

10.1111/j.1365-2125.1987.tb03072.x

Cite

Citations (33)